Software Effective Solutions - SFWJ STOCK NEWS

Software Effective Solutions Corp. (OTC:SFWJ), operating as Medcana, has announced its strategic expansion into the Australian market through the acquisition of pharmaceutical cannabis import and distribution licenses. The move represents a significant milestone in the company's global growth strategy.

The newly acquired licenses will enable Medcana to import and distribute pharmaceutical-grade cannabis products in Australia, allowing the company to establish distribution partnerships and meet the growing regional demand for medical cannabis. This expansion strengthens Medcana's international presence, particularly in Latin America and the Asia-Pacific region.

Medcana (OTC PINK:SFWJ) has announced the cancellation of 86,916,294 shares of its Common stock. The shares, which were issued several years ago and held in book entry by the transfer agent, will be fully canceled without any new shares being issued as replacement.

This strategic move is part of the company's efforts to reduce the share structure inherited from its shell merger. CEO José Gabriel Díaz described this as an 'excellent first step' while highlighting the company's progress in advancing operations in Colombia.

Medcana operates as a U.S.-based public company in the international medical cannabis sector, focusing on production, research, and global distribution of pharmaceutical-grade cannabis products through its Colombian operations and strategic partnerships.

Software Effective Solutions Corp. (OTC PINK:SFWJ), operating as Medcana, has successfully completed its first pharmaceutical-grade CBD crop export through Colombian partner Anutea S.A.S. The export to Switzerland surpassed initial projections, yielding 18 kilograms of premium CBD flower compared to the expected 10 kilograms.

The inaugural shipment generated modest revenue of $2,500 but demonstrates Medcana's capability in compliant international cannabis trade. The company views this milestone as validation of their supply chain logistics and compliance processes, laying groundwork for larger future orders as they complete construction of their new 58,000 sq ft greenhouse.

MedCana (OTC: SFWJ), a pharmaceutical-grade cannabis industry infrastructure holding company, has announced significant achievements in its latest CBD harvest, with yields exceeding double the expected amount with no operational issues. The company has secured sales agreements for its entire production over the next 12 months.

MedCana has begun construction of a new 53,800-square-foot facility designed to house 14,000 plants with an expected monthly yield of 350 KG. The company projects revenue between $1.2 million and $1.5 million per hectare per month based on current market conditions and expansion plans.

MedCana (OTC: SFWJ), a global infrastructure holding company in the pharmaceutical-grade cannabis industry, has announced that one of its Colombian subsidiaries is in negotiations with an Australian pharmaceutical firm for a medical-grade cannabis supply agreement. The deal is expected to generate $100,000 to $200,000 in monthly revenue, potentially reaching $1.2 to $2.4 million annually.

CEO Jose Gabriel Diaz described this as a pivotal moment for MedCana's global expansion to meet the growing demand for pharmaceutical-grade cannabis. MedCana, formerly known as Software Effective Solutions, is focused on developing companies in the agricultural technology and cannabis industries.

MedCana (OTC PINK:SFWJ), a global infrastructure holding company in the pharmaceutical-grade cannabis industry, has announced multiple acquisitions and associated cannabis licenses. The company has acquired a total of 23 licenses, including 7 CBD licenses, 7 THC licenses, 7 licenses for fabrication of cannabis-containing products, and 2 genetics licenses. These acquisitions will add $1.6 million to MedCana's total assets for the 3rd Quarter.

The acquisitions include 100% ownership of several companies: Cannabicolombia group s.a.s., Cannehealth Business s.a.s., Organic Leaves S.A.S., Remedium S.A.S, Royal Cannabis S.A.S, Vital Cannabis S.A.S, and Elemental Genetics S.A.S. Additionally, MedCana has acquired a controlling stake in Eko2o Environmental Solutions S.A.S., a company focused on developing infrastructure for agriculture in Colombia and South America.

MedCana (OTC: SFWJ), a holding company specializing in agricultural technology and the cannabis industry, is exploring opportunities to enter the Australian pharmaceutical cannabis market. The Australian legal cannabis market is projected to reach USD 540.6 million by 2030, with a CAGR of 27.8% from 2024 to 2030.

MedCana aims to establish a presence as both an exporter and licensed producer in Australia. The company's CEO, Gabriel Diaz, highlighted the growing demand for high-quality pharmaceutical cannabis as a perfect opportunity for rapid expansion. MedCana is committed to meeting Australia's rigorous pharmaceutical standards by ensuring all its subsidiaries follow Good Agricultural and Collection Practices (GACP) certification processes.

The expansion into Australia aligns with the country's increasing patient demand, favorable regulatory changes, and expanding access to medicinal cannabis treatments.

SFWJ, operating as MedCana, a cannabis and agricultural technology holding company, has announced the elimination of all Convertible Debt from its Balance sheet by the end of the 3rd Quarter. The company is set to remove $450,000 of convertible debt, with debtholders agreeing to swap their debt for Preferred shares carrying the same rights and interest rate. This move aims to boost investor confidence and prepare the company for its next growth phase.

As part of the agreement, the new preferred shareholders have committed to a 6-month lock-up period. MedCana's CEO, Gabriel Diaz, emphasized the company's focus on revenue growth and enhancing shareholder value, assuring investors that they need not worry about debt conversion impacting their share value.

SFWJ, operating as MedCana, has announced a strategic partnership with a local Colombian company to start exporting CBD buds to Switzerland within six months. This partnership is a significant step in MedCana's European market expansion and highlights its commitment to delivering high-quality CBD products. MedCana CEO Gabriel Diaz emphasized the importance of this collaboration in strengthening the supply chain and penetrating the Swiss market, a vital area for growth. The Colombian partner's expertise in cultivation and processing will be instrumental in meeting stringent Swiss quality standards, aligning with MedCana's goals of sustainable agricultural practices and international market growth.